Ruxolitinib therapy and telomere length in myelofibrosis

Blood Cancer J. 2016 Oct 7;6(10):e479. doi: 10.1038/bcj.2016.91.

Authors

G Caocci¹, M Greco¹, G Delogu², C Secchi^{2

3}, A Perra¹, S Ghiani¹, F Orru¹, A Vacca¹, F Galimi^{2

3}, G La Nasa¹

Affiliations

¹ Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
² Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
³ National Institute of Biostructures and Biosystems, University of Sassari, Sassari, Italy.

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Case-Control Studies
Female
Humans
K562 Cells
Male
Middle Aged
Nitriles
Primary Myelofibrosis / drug therapy*
Primary Myelofibrosis / genetics
Primary Myelofibrosis / pathology
Pyrazoles / therapeutic use*
Pyrimidines
Telomere / drug effects*
Telomere / metabolism
Telomere Homeostasis / drug effects*
Treatment Outcome

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib